Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a report released on Saturday. The brokerage set a "hold" rating on the stock. Shares of Brooklyn ImmunoTherapeutics stock opened at $3.65 on Friday.
Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a note issued to investors on Thursday. The firm set a "hold" rating on the stock. BTX opened at $0.25 on Thursday.
Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Research Coverage Started at StockNews.com
Analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a report issued on Wednesday. The brokerage set a "hold" rating on the stock. NYSE:BTX opened at $0.23 on Wednesday.
Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Now Covered by StockNews.com
StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock. Shares of Brooklyn ImmunoTherapeutics stock opened at $0.29 on Tuesday.
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics ( NYSE:BTX )
StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a report issued on Monday. The firm issued a hold rating on the stock. Shares of BTX stock opened at $0.36 on Monday.
Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a research note released on Wednesday. The firm issued a hold rating on the stock. Shares of BTX stock opened at $0.34 on Wednesday.
Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study
Brooklyn ImmunoTherapeutics Inc BTX has announced results from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. BTX ( "Brooklyn" or the "Company" ) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell ...
Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics ( NYSE:BTX - Get Rating ) in a research report issued on Tuesday. The firm set a "sell" rating on the stock. Shares of BTX stock opened at $0.59 on Tuesday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.46 and a 1-year ...
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SAN DIEGO, June 17, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( Nasdaq:BTX ) ( "Brooklyn" or the "Company" ) , a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, ...
18 Stocks Moving in Friday's Pre-Market Session
Gainers The Marygold Companies, Inc. ( NYSE: MGLD ) rose 38.8% to $2.04 in pre-market trading. Marygold Companies, last month, posted Q1 earnings of $0.02 per share. Energy Focus, Inc. ( NASDAQ: EFOI ) shares rose 21.5% to $1.35 in pre-market trading after declining around 9% on Thursday. Okta,
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
SAN DIEGO, May 31, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( Nasdaq:BTX ) ( "Brooklyn" or the "Company" ) , a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with can
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
SAN DIEGO, May 31, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( NASDAQ:BTX ) ( "Brooklyn" or the "Company" ) , a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with can
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
SAN DIEGO, May 27, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( Nasdaq:BTX ) ( "Brooklyn" ) , a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic dis
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
SAN DIEGO, April 21, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( NASDAQ:BTX ) ( "Brooklyn" ) , a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood diso
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, April 15, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( Nasdaq:BTX ) ( "Brooklyn" ) , a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic d
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
NEW YORK, March 09, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( NASDAQ:BTX ) ( "Brooklyn" ) , a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic dis
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
NEW YORK, March 09, 2022 ( GLOBE NEWSWIRE ) -- Brooklyn ImmunoTherapeutics, Inc. ( Nasdaq: BTX ) ( "Brooklyn" ) , a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic di
